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al lmeo dianneter increased 
Coronary stems have been proposed as a means of overcoming 
two major limitations of balloon angiopiasty-sudden early 
vessel closure and late restenosis. The initial enthusiasm for 
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any adverse! clinical event 
the native coronargt circulation is associated with a low restemsis 
ive aogio eviouslgr nntreeated lesions 
dinical %a an eweknt event-free 
year. 
this technology has been dampened byreports of high rates of 
thrombosis for self-expanding stents (1). The device used in 
this trial was a balloon-expandable, stainless steel stent 
(Paimaz-Schatz stent) whose initial efficacy has been described 
(2). I’revious studies (2-4) have included patients who differed 
in clinical indications for device placement, baseline character- 
istics and the use of multiple or single stents. The specific goal 
of this study was to assess angiographic restenosis and iong- 
term clinical outcome in a consecutive s ries of patients 
undergoing elective revascuiarization witha single Paimaz- 
Schatz stent. 
evice description, The 15-mm long Palmaz-Schatz stem is 
composed of two 7-mm rigid, slotted stainless teel tubes 
connected by a l-mm central bridging strut (Johnson and 
Johnson Interventional Systems). In the first 30 patients, a 
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prototype device without a central stmiit was used. When 
expanded by a standard 20-mm length angioplasty balloon, the 
rectangular slots take on a diamond-shaped configuration with 
a large free space/metal ratio. In its deployed slate, the device 
has a high level of radial noncompliance, thereby resisting 
compressive forces and elastic recoil. The individual metal 
struts are 0.12 mm wide and 0.06 mm thick. Previous canine 
experiments (5) have shown that the stent is covered by a 
platelet fibrin mesh within hours of implantation and is fully 
endothelialized within 4 weeks. 
Before stent placement, all lesions were pretreated by 
dilation using conventional angioplasty balloons. The SFenF was 
deployed by inllating the delivery balloon to S to 6 bar. Procedural 
detailsofstent placement have been described previously (2). The 
adjunctive pharmacologic imen was as follows: 
tation, patients recqivcd rin (325 mg), dipyridamole (73 mg 
three times a day), a calcium antagonist and low molecular weight 
defiran 40 (be8tm 2 h 100 ml/h). During the 
procedure, patients rece b&s of hcparin with a 
Lwntinuous infusion at 9 e activaad clotting time 
was maintained at >300 s). Treatment with warfarin was started 
on the day of the procedure. After the procedure, heparin 
infusion was temporarily discontinued and femoral sheaths were 
removed when the activated clotting time was <l&l s; heparin 
treatment was restarted 6 h later and continued until a Fherapeu- 
tii prothrombin time was achieved with warfarin. Warfarin was 
given for 1 month and dipyridamole for 3 months; aspirin therapy 
was continued indctinitely. 
tients. The study group consisted of 300 consccu- 
tive patients who underwent elective pkNXmeflF of a single 
Palmaz-Schatz stent in a native coronary artery between 
December 1987 and June 1990. The protocol was approved by 
the hkItituFional Review Boards of the I2 participating sites 
and informed consent was obtained from all patients. During 
this study period, an additional 73 patients underwent coronary 
stcnting on an unplanned, emergency “bailout” basis outside 
of the present protocol oe with use of multiple stents, or both. 
The clinical characteristics of the patients are shown in 
Table I. Inclusion and exclusion criteria for enrollment into 
this trial as well as the immediate results after stenting have 
been previously described in detail (2). Eligibility criteria for 
stenting included objective evidence of myocardial ischemia, 
presented left ventricular ejection fraction aSO%, a coronary 
StemSiS 270% (by visual estimate of the investigator) that 
m&i be completely spanned by a single IS-mm long stent, and 
a target vessel diameter 13 mm. Follow-up catheterization was 
performed at 6 months after stem implantation unless early 
restudy was indicated by symptoms. To assess the possibility 
that the metal implant might prolong the time course of 
resteno& a second follow-up angiogram was performed on a 
prospective basis at 1 year in a cohort of SO patients. Clinical 
follow-Up status was obtained at 1 and 2 weeks and at 1, 2,3, 
6 and 12 months. Tbr: major clinical events assessed for this 
study were death, myocardial infarction and need for repeat 
revascularization. 
Table 1. Clinicai flharacteristics of 300 study Patients 
Age w 
Male/female 
Angina class (CCS) 
238/b? 
~~~~~~ ane@$s. Initial and folf~)\v~~~ i~Il8i~)gral~~s 
were forwarded to th hit 
Thomas Jefferson Wniv 
lyzed by a panel of ex 
elsewhere (6). Coron 
administration of intrac~ro~a~ ~iFroglyceri~ (150 to 200 @g) 
at baseline, after balloon angioplasty, after stent im~la~taFion 
and at the 6-month follow-~~ study. 
Quantitative analysis of the coronary se8~~e~ls of ~~~~~~sF 
were performed by using a validated computer-bases edge 
detection algorithm (7,8). Cine frames. in orthogonal views 
whenever possible, were selected by the panel re coronary 
~~~~~o~I~sIY, after ballotln di~at~~~, after stent i ntation and 
at follow-up. These tine frames were projected on a General 
Electric Caps 35mm tine viewer optically coupled to a video 
camera. The video signal was digitized at 512 X 512 X 8-bit 
resolution onto a digital angiographic computer (model DFS- 
4100, ADAC Laboratories). Images were magnified fourfold 
and the region of interest was selected by the operator and the 
vessel lumen was automatically determined (Artrek program, 
ADAC Laboratories). Absolute measurements were made 
using the dye-filled guiding catheter as a scaling reference. The 
proximal and disFal segments considered to be normal and 
outside the stented area were selected by the operator and 
averaged to determine the reference vessel dimension. Mini- 
mal lumen diameter, reference vessel diameter and percent 
diameter stenosis were then calculated as a mean value from 
the hvo orthogonal projections. The mean variability for 
repeated measurements performed by the core laboratory 
on different days is ~0.16 mm for minimal lumen diameter 
and 24.2% for percent diameter stenosis. 
End points. Restenosis was defined as ~50% diameter 
stenosis on the follow-up angiogram. The following events 
were considered clinical end points: death, myocardial infarc- 
tion, bypass surgery and repeat angioplasty during the 1st year. 
All myocardial infarctions were documenter according to the 
criteria of the National Heart, Lung, and Blood Institute 
Percutaneous Transluminal Coronary Angioplasty Registry 
described by Detre et al. (9), with at least FWO of the following: 
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cal sy~~to~ls, presence of 
*Ition in creatine kinase or 
times the upper limit of normal. 
is. All data are expressed as mean value +
S mong baseline, po ~gio~~asty and post- 
stent meas~reme~ts were two-way analysis of 
variance. Two-tailed I tests were applied for analysis of paired 
numeric data. The chi-sq are test was used to assess the 
of categoric varia biographic restenosis. A 
statistical probability of < 0.05 was consldered significant. 
There were no acute in-laboratory vessel closures. Fourteen 
(4.7%) of 300 ~~t~~~t~ developed stent thrombosis at 5 f 3 
days after stent il~l~~a~tation (range 0 to 12 days). Of the 286 
remaining eligible patients, 258 (90%) had late angiographic 
follow-up at 6.1 it 2.2 months after stent implantation (Fig. 1). 
Clinical follow-up was obtained on all 300 patients at 12 
months. 
A aphic outcome. Eighty-three patients (28%) had 
not usly undergone angioplasty of the study lesion. 
Eighty-six patients (29%) had one previous angioplasty proce- 
dure, and 131 patients (43%) had two or more previous 
angioplasty procedures. Thus, 72% of the stents were placed 
for restenotic lesions. Qualitative lesion characteristics before 
intervention are summarized in Table 2. Unfavorable morpho- 
logic features included eccentricity n 57%, complex ulceration 
in 36%, and intimal dissection resulting from angioplasty in 
29%. 
Baseline minimal lumen diameter was 0.80 + 0.39 mm; this 
value increased to 1.65 + 0.51 mm x1ter initial angioplasty (p = 
0.0001) and increased significantly further to 2.55 ? 0.49 mm 
after stent implantation (p = 0.0001). At 6-month follow-up, 
there was a net late loss of 0.85 mm to a final minimal lumen 
diameter of 1.70 -C 0.71 mm (p = 0. 
post-stent value). In Figure 2, these rew” depicted using 
Baseline Lesion Characteristics 
Vessel diameter (mm) (mean f SD) 
Lesion length (mm) (mean + SD) 
Site of stent i~~~~a~~a~ion (%‘c) 
Left main coronary artery 
Left anterior descending coronary artery 
Left circumflex coronary artery 
Right coronary artery 
Morphologic feature of lesion (c/F) 
Eccentric 
Ulcerated 
Calcification 
Bend 245” 
Thromhus 
Dissection after balloon imgioplasty 
cumulative frequency of lesions plotted as a function of the 
~ilii~~i~~~ lumen diameter. 
in 14% of the previously untreated 
reviously dilated 
restenosis rates were 43% and 30%, 
respectively, for lesions with one, two and three or more 
previous angioplasty procedures (Fig. 3). For lesions that had 
previously been dilated, there was no significant increase in 
restenosis risk as a function of the number of previous 
procedures. 
Restenosis was not significantly a cted by the location of 
the vessel stented. Restenosis rates of stents placed in the left 
anterior descending, left circumflex and right coronary artery 
were 37%, 26% and 29%, respectively (p = NS). In addition, 
restenosis was not influenced by the reference vessel size or 
morphologic features, such as eccentrici!y, calcification, plaque 
ulceration or the presence of a postangioplasty dissection. 
When an optimal angiographic result with a rtasidual stenosis 
of ~10% was achieved by initial stent placement, restenosis 
Figure 2. Cumulative frequency plot of perceni of lesions as a function 
of the minimal lumen diameter. The graphs show that stem impianta- 
tion was associated with a significant gain compared with results for 
coronary angioplasty (PTCA); there was subsequent loss of initial gain 
at follow-up because of intimal hyperplasia. 
60 
40 
0 Baseline 
A PTCA 
0 STEPJT 
0 Follow-up 
1 2 3 4 5 
Minimal Lumen Diameter (mm) 
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MO. Prior PTCA 
Figure 3, Restenosis after stent implantation. The restenosis rate is 
plotted for previously untreated lesions (open bar) and for lesions with 
one, two and three or more previous coronary angioplasty procedures 
(batched bars). The restenosis rate for previously untreated lesions 
was significantly less than that for lesions with previous angioplasty 
(p C 0.001). However, for lesions that were previously dilated, restenosis 
did not progressively increase as a function of the number of previous 
angioplasty procedures, suggesting a restcnosis “plateau” for stents. 
occurred in 27% of vessels versus 36% for lesions with a 
greater residual stenosis after stent placement (p= 0.13). 
Late an&graphic follow-up at 1 year. To assess whether 
the permanent metallic mplant prolongs the time course over 
which intimal hyperplasia occurs, quantitative angiography was 
performed in a cohort of 50 patients who underwent a second 
follow-up catheterization at 1 year (Fig. 4 and 5). Lumen 
diameter was significantly smaller at 6 months than immedi- 
ately after stenting (1.88 2 0.51 mm vs. 2.54 t 0.40 mm, p = 
O.OOOI). In contrast, there was no further decline in minimal 
lumen diameter between 6 and 12 months (1.90 f 0.48 mm at 
12 months vs. 1.88 ?r 0.51 mm at 6 months, p = NS). Similar 
findings were observed for percent diameter stenosis. Mean 
percent s enosis was 16 3: 13% at implantation, 34 t 17% at 
6 months and 34 L 16% at 1 year. Angiographic restenosis 
(250% diameter stenosis) inthis cohort was 18% (9 of 50) at 
6 months vefsus 16% (8 of 50) at 1 year. 
ClInleal outcome. Clinical end points at l-year follow-up 
are shown in Table 3. All adverse vents, whether they 
occurred inthe hospital or during late follow-up, were included 
in this analysis. The overall mortality rate was 0.7%. Myocar- 
dial infarction occurred in 11 patients (3.7%), including 7
(2.3%) with a Q wave infarction and 4 (1.3%) with a non-Q 
wave infarction. In 10 of these 11 patients, myoeardial infarc- 
tion was due to subacute stent thrombosis. In contrast, acute 
myocardial infarction after I year developed inonly 1 (0.3%) 
of the 286 patients in whom early stent hrombosis did not 
occur. 
For the entire study group, 80% of patients remained free 
after 1 year from any adverse clinical event (death, myocardial 
infarction or additional revascularization). Of the subgroup 
with previously untreated lesions, 87% were event-free; of the 
patients with prior aagioplasty procedures, 77% were event- 
free. 
In addition to the major adverse clinical end points just 
described, bkeding complications requiring either peripheral 
31 
2- 
1’ 
oJ-------” - 
Baseline Went 6 Months 12 Months 
Figure cl. Temporal course of restenosis after intracoronary stent 
implantation. Quantitative coronary angiography was performed in 50 
patients at baseline, immediately after stem placement, at 6 months 
after placement and again at 1 year. A significant loss in minimal 
lumen diameter (MLD) was noted during the 1st 6 months but not 
during the interval from 6 to 12 months, indicating that the presence of 
the endovascular prosthesis does not delay the usual time course of the 
rsstenosis process. 
vascular surgery or blood transfusion ccurred in 31 patients 
(10%). There were no instances of intracerebral hemorrhage 
in this study. 
Discussisn 
This consecutive s ries of 300 patients with a 90% angio- 
graphic restudy rate demonstrates hat implantation f single 
balloon-expandable Pa maz-Schatz s ents is associated with 
excellent event-free survival after 1 year and a low angio- 
graphic restenosis rate in previously untreated lesions. 
Comparison with previous studies. Previous reports of a 
self-expanding stern have shown excellent acute anglographic 
results with substantial improvement i  lumen diameter imme- 
diately after stent implantation. Serruys et al. (1) reported an 
increase of lumen diameter f om 1.21 mm at baseline to 
1.88 mm after coronary angioplasty to 2.48 mm after stent 
placement. However, despite the improved angiographic ap- 
pearance of the vessel after stent implantation compared with 
the result after angioplasty, a significant clinical benefit was not 
seen. Thrombosis occurred within 2 weeks in 25 (24%) of 105 
patients and the l-year mortality rate was an unacceptable 
7.6%. Restenosis, defined as 150% narrowing at 6-month 
follow-up angiography, occurred in14%. 
The results of our study show that the long-term clinical 
outcome associated with the balloon-expandable stent is in 
sharp contrast to this earlier eport. Despite similar quantita- 
tive angiographic results measured at the time of stent implan- 
tation, the rates of thrombosis and death were markedly ower 
in the current series. Our quantitative angiographic results 
show a very similar final stent minimal lumen diameter of 
2.55 mm. However, thrombotic o clusion ofthe stent occurred 
in <5% and the l-year mortality rate was cl%. Thus, despite 
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we 5. Serial coronary angio- 
grams from a 48-year old man wiz 
SENT) left coronary angiography 
de~ons~ra~~s  highgrade stenosis 
the ramus medianus brunch 
rowpI which is reduced 10 a min- 
nveen 6and 12 months, no further 
change inthe lesion is observed. 
a similar excellent immediate a ic result, the reduced 
outcome. Resten 
ll~~t~e~ted lesions 
the prior study (14%). The differences in t 
occlusion may be related to several factors 
ences in device design, ant~c~gnlation regimens an 
patient characteristics. 
A single-center study (3), using the almazSchatz stent in 
both the native arteries and venous byp s grafts, has reported 
an even lower thrombosis rate of 0.4%, However, the varying 
biologic behavior of bypass grafts compared with native vessels 
with respect to thrombosis may account in part for these 
optimistic results (10). 
The time course of abrupt closure associated with stenting 
is different from that observed with conventional balloon 
angioplasty. Although there were no immediate in-laboratory 
vessel closures in our 300 patients, delayed thrombotic occlu- 
sion occurred in slightly less than 5% of the Palmaz-Schatz 
stents. This complication accounted for nearly all acute isch- 
emit complications and, therefore, r presents he most serious 
limitation of this therapy. Acute myocardial infarction devel- 
oped b 10 of 14 patients with stent hrombosis but in only 1 of 
286 patients without hrombosis. Accordingly, efforts to lessen 
this complication by improved techniques ofstent deployment 
an ntithrombotic coatings ar er development. 
anism of benefit conferr stents. The restenosis 
rate of 14% noted in the group with previously untreated 
lesions is in sharp contrast o the restenosis rates of 30% to 
Table 3. Clinical Follow-Up at 1 Year 
12 
ted after conventional balloon angioplasty (1l-17). 
anism by which stents reduce restenosis can be 
ribu~e~ to the enhanced immediate gain that is achieved 
compared with that after balloon angioplasty rather than to a 
reduction of late loss due to intimal hyperplasia (3J8). Thus, 
stc~~t~ng of previously untreated lesions results in a wider initial 
lumen that can acco modate a relatively larger degree of 
neointimal ingrowth without producing a severe diameter 
stenosis. In contrast, higher ates of angiographic stenosis are 
observed for stents placed into restenotic lesions previously 
treated by balloon angioplasty. In addition, earlier reports of 
the Palmaz-Schatz stent (3,18) have shown a marked increase 
in restenosis rates when rnnlt~~~e stents are placed. For this 
reason, we chose to study patients who had implantation of a 
e stent. 
ate clinical outcs ients after cn~~na~ stent 
The clinical outcomes noted in our study com- 
favorably with those reported in r studies of standard 
balloon angio?lasty. In the National art, Lung, and Blood 
Institute Percutaneous Transluminal Coronary Rngiopksty 
Registry of 1985 to 1986 (9), major adverse vents in 1,801 
patients after 1 year of follow-up included death in 3.2%, 
myocardial infarction in 7.2%, coronary bypass grafting in 
13.2% and repeat coronary angioplasty in 18.5%. Thirty-four 
percent of patients experienced one or more of these adverse 
events within 1 year. In the present stent series, the cumulative 
frequency of any adverse clinical event at 1 year was 20% for 
the entire study group and only 13% in the group with 
previously untreated lesions. These comparisons should be 
Repeat 
Patient Group No. Death M1 CABG Angioplasty No Event 
All piitients 300 I (0.7%) 11 (3.7%) 24 (8.0%) 39 (13.0%) 240 (80%) 
No prior angioplasty 83 1(1.2%) 4 (4.8%) 7 (8.4%) 6 (7.2%) 72 (87%) 
Prior angioplasty 217 I (OS%) 7 (3.2%) 17 (7.8%) 33 (15.2%) 168 (77%) 
Stent thrombosis 14 1(7.1%) IO (71.4%) 7 (50.0%) 9 (64.3%) 1(7%) 
No thrombosis 286 1(0.3%) 1 (0.3%) 17 (5.9%) 30 (10.5%) 239 (84%) 
Values are expressed as number (%) of patients. CABG = coronary artery bypass graft surgery; MI = myocardial 
infarction. 
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made with caution because of differences in patient groups and 
fie evolution of standard angioplasty echniques since the 
National Heart, Lung, and Blood Institute report. 
L&I&&B of the present study. This study has several 
important limitations. Fit, there was no concurrent control 
group of patients undergoing standard angioplasty for defini- 
tive comparisons to be made regarding stent implantation. 
Second, the number of patients reported in the group with 
previously untreated lesions was relatively small so that gcn- 
eralizations regarding restenosis rates in patients undergoing 
first-time r v,zs~!r...tion are not yet warranted. Third, there 
were no data presented onthe cost/benefit ratio for a proce- 
dure that prolongs hospital stay and incurs a substantial 
increase inshort-term charges (19). 
Cllnlal implhtioa& Our data show that elective implan- 
tation of single Palmaz-Schatz stems in large native coronary 
arteries i  associated with excellent long-term patency. In 
addition, this p-rmanent i ravascular implant does not pro- 
long the temporal course of the restenotic process as demon- 
strated by follow-up angiography at 1 year. Most important, 
intracoronary stents conferred an excellent long-term clinical 
outcome. The incidence ofdeath, myocardial infarction and 
the need for further revascularization pr cedures appears low 
when compared with findings in previous reports of standard 
balloon angioplasty or self-expanding stents. However, the 
potential for early coronary thrombosis and a relatively high 
rate of peripheral vascular complications remain major limita- 
tions of stenting. The findings of this multicenter study pro- 
vided the framework leading to the Stent Restenosis Study 
(STRESS), a randomized trial comparing elective stent place- 
ment o balloon angioplasty in the treatment of previously 
untreated iesions in native coronary arteries. 
We am indebted to Damthy Lennox and Marilyn Gangemi for assistcnce in 
preparing the manuscript, and to Sally Levine for assistance with data collection. 
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